drugset / Trial / NCT06601127

Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).

NCT06601127

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to evaluate efficacy and safety of tiprogrel in the treatment of patients with acute ischemic cerebrovascular events.

Timeline

Start
2025-02-21
Primary completion
2026-04-01
Completion
2026-06-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clopidogrel Small molecule
Subject Tiprogrel Unknown
Background Aspirin Small molecule

Indications